HSF Danby Research Grant Program supports investigators pursuing clinical and translational research on hidradenitis suppurativa to advance patient care, raise disease awareness, or enable further funding.
Funder: Hidradenitis Suppurativa Foundation
Due Dates: December 7, 2026, at midnight (Application)
Funding Amounts: Up to $30,000 in direct costs for one year; four grants anticipated annually
Summary: Supports new clinical and translational research on hidradenitis suppurativa that advances patient care.
Key Information: Only investigators working in the United States are eligible; early-stage investigators receive priority.
The Hidradenitis Suppurativa Foundation (HSF) funds the Danby Research Grant Program to develop new clinical and translational lines of investigation in hidradenitis suppurativa (HS). The program supports innovative, well-reasoned research that advances patient care, raises disease awareness, or generates findings that can lead to additional research funding.
Proposals are assessed for their relevance to HS, scientific approach, investigator capability, and diversity of the research team and planned patient cohort. Applicants should explain potential problems, alternative strategies, benchmarks for success, and how findings could affect patient care. Clinical trials are strongly discouraged because the funding is considered inadequate to support a robust trial.